# Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

> **NCT05187338** · PHASE1,PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Lung Cancer
- Liver Cancer
- Colorectal Cancer
- Pancreas Cancer
- Ovary Cancer
- Head and Neck Cancer
- Breast Cancer
- Gastric Cancer
- Cervical Cancer
- Esophageal Cancer
- Sarcoma

## Interventions

- **DRUG:** ipilimumab +pembrolizumab +durvalumab

## Key facts

- **NCT ID:** NCT05187338
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2029-10-30
- **Final completion:** 2035-10-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05187338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05187338, "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT05187338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*